Below are the most recent publications written about "Niacinamide" by people in Profiles.
-
Park KH, Kim SH. Adult zebrafish as an in vivo drug testing model for ethanol induced acute hepatic injury. Biomed Pharmacother. 2020 Dec; 132:110836.
-
Harlan BA, Pehar M, Killoy KM, Vargas MR. Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1. FASEB J. 2019 06; 33(6):7084-7091.
-
Huang F, Ajavon A, Huang E, Lettieri J, Liu R, Peña C, Berse M. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. Thyroid. 2017 09; 27(9):1118-1127.
-
Ding X, Chaiteerakij R, Moser CD, Shaleh H, Boakye J, Chen G, Ndzengue A, Li Y, Zhou Y, Huang S, Sinicrope FA, Zou X, Thomas MB, Smith CD, Roberts LR. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016 Apr 12; 7(15):20080-92.
-
Wong CJ, Witcher J, Mallinckrodt C, Dean RA, Anton RF, Chen Y, Fijal BA, Ouyang H, Dharia S, Sundseth SS, Schuh KJ, Kinon BJ. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb; 38(2):511-20.
-
Tripathi K, Matmati N, Zzaman S, Westwater C, Mohanty BK. Nicotinamide induces Fob1-dependent plasmid integration into chromosome XII in Saccharomyces cerevisiae. FEMS Yeast Res. 2012 Dec; 12(8):949-57.
-
Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51.
-
Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38.
-
Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011 Mar 01; 11(5):524-34.
-
Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 2010 Aug; 9(8):2220-31.